title: Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial.
abstract: OBJECTIVE
  Microalbuminuria frequently clusters with the metabolic syndrome and may identify subjects at increased coronary risk. Statin treatment may reduce the incidence of major adverse cardiac events in subjects with the metabolic syndrome, but evidence is limited. We evaluated the impact of pravastatin treatment on the incidence of major adverse cardiac events in microalbuminuric subjects with the metabolic syndrome.
  
  
  RESULTS
  This substudy of the PREVEND Intervention Trial (a randomized, placebo-controlled trial with a 2x2 factorial design) included 864 microalbuminuric subjects, who were randomized to fosinopril 20 mg or matching placebo and pravastatin 40 mg or matching placebo (mean follow-up 46 months). The metabolic syndrome was defined according to the NCEP ATPIII-report. Subjects with or without the metabolic syndrome were characterized by a higher age, male sex, and increased albuminuria. The incidence of major adverse cardiac events in subjects with the metabolic syndrome [9.1%; 95% confidence interval (CI) 6.0-13.0%] was increased vs. those without [3.6%; 95% CI 2.3-5.5%; P=0.007). Pravastatin treatment lowered the incidence of major adverse cardiac events in subjects with the metabolic syndrome after adjustment for age and sex (hazard ratio=0.39; 95% CI 0.17-0.89; P=0.025).
  
  
  CONCLUSIONS
  This study supports the use of statins in microalbuminuric subjects with the metabolic syndrome to reduce the incidence of major adverse cardiac events.
authors.affiliation: Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, Postbus 30001, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. c.a.geluk@thorax.umcg.nl
authors.forename: Christiane A
authors.initials: CA
authors.lastname: Geluk
authors.forename: Folkert W
authors.initials: FW
authors.lastname: Asselbergs
authors.forename: Hans L
authors.initials: HL
authors.lastname: Hillege
authors.forename: Stephan J L
authors.initials: SJ
authors.lastname: Bakker
authors.forename: Paul E
authors.initials: PE
authors.lastname: de Jong
authors.forename: Felix
authors.initials: F
authors.lastname: Zijlstra
authors.forename: Wiek H
authors.initials: WH
authors.lastname: van Gilst
mesh_terms: D000419:Albuminuria / Q000150:complications*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003327:Coronary Disease / Q000150:complications*; D004311:Double-Blind Method; D005260:Female; D017328:Fosinopril / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin; D017328:Fosinopril